Patient-Derived Xenograft Models for Endometrial Cancer Research

dc.contributor.authorMoiola, Cristian P.
dc.contributor.authorLopez Gil, Carlos
dc.contributor.authorCabrera, Sílvia
dc.contributor.authorGarcia, Angel
dc.contributor.authorVan Nyen, Tom
dc.contributor.authorAnnibali, Daniela
dc.contributor.authorFonnes, Tina
dc.contributor.authorVidal-Bel, August
dc.contributor.authorVillanueva Garatachea, Alberto
dc.contributor.authorMatias-Guiu, Xavier, 1958-
dc.contributor.authorKrakstad, Camilla
dc.contributor.authorAmant, Frédéric
dc.contributor.authorGil Moreno, Antonio
dc.contributor.authorColás, Eva
dc.date.accessioned2020-04-27T09:55:48Z
dc.date.available2020-04-27T09:55:48Z
dc.date.issued2018-08-17
dc.date.updated2020-04-27T09:55:48Z
dc.description.abstractEndometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool for translational research, since they closely resemble patient tumour features and retain molecular and histological features. In EC, PDX models have already been used, mainly as an individualized approach to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and represent an excellent reservoir of EC tumour samples for translational research. This review compiles the information on current methods of EC PDX generation and their utility and provides new perspectives for the exploitation of these valuable tools in order to increase the success ratio for translating results to clinical practice.
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec681592
dc.identifier.issn1661-6596
dc.identifier.pmid30126113
dc.identifier.urihttps://hdl.handle.net/2445/157640
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms19082431
dc.relation.ispartofInternational Journal of Molecular Sciences, 2018, vol. 19, num. 8, p. 2431
dc.relation.urihttps://doi.org/10.3390/ijms19082431
dc.rightscc-by (c) Moiola, Cristian P. et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationCàncer d'endometri
dc.subject.classificationAparell genital femení
dc.subject.classificationMedicina personalitzada
dc.subject.otherEndometrial cancer
dc.subject.otherFemale generative organs
dc.subject.otherPersonalized medicine
dc.titlePatient-Derived Xenograft Models for Endometrial Cancer Research
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
681592.pdf
Mida:
1.13 MB
Format:
Adobe Portable Document Format